Literature DB >> 28223874

Towards safety of oral anti-cancer agents, the need to educate our pharmacists.

Sanaa Saeed Mekdad1, Adher Dhaya AlSayed2.   

Abstract

Introduction: The global prevalence of cancer is rising. Use of oral anticancer medications has expanded exponentially. Knowledge about these medications as well as safe handling guidelines has not kept abreast with the rapidity these medications are applied in clinical practice. They pose serious hazards on all personal involved in handling these medications as well as on patients and their caregivers. We addressed the gaps in knowledge and safe handling of oral anticancer agents among pharmacists in institutional based cancer care. Materials and
Methods: We used a 41 item questionnaire to explore three domains, pharmacists' knowledge, safe handling practice and confidence and self-improving strategies towards these agents among pharmacists in multicentre specialized cancer care.
Results: Participants included 120 pharmacists dedicated to handle and dispense oral anticancer agents. About 20% of Pharmacists have adequate knowledge about oral anticancer agents. Less than 50% apply safe handling principles adequately. Only a quarter are confident in educating cancer patients and their caregivers about Oral Anti-Cancer Agents. Conclusions: Pharmacists' knowledge about Oral Anticancer agents needs to be improved. Safe handling and dispensing practice of these medications should be optimized. Pharmacists' confidence towards educating patients and their caregiver needs to be addressed. Enhancing safety of oral anticancer agents should be a priority. Involving all key players, research and quality improving projects are needed to improve all aspects of the safety of oral anticancer agents.

Entities:  

Keywords:  Cancer; Medication knowledge; Oral anticancer agents; Pharmacists; Safe handling

Year:  2015        PMID: 28223874      PMCID: PMC5310136          DOI: 10.1016/j.jsps.2015.06.007

Source DB:  PubMed          Journal:  Saudi Pharm J        ISSN: 1319-0164            Impact factor:   4.330


Introduction

The cancer burden is rising in many developing countries. It is projected that cancer incidence will increase form 12.7 million in 2008 to 22.2 million by 2030 (Bray et al., 2012). The first oral anti-cancer chemotherapy dates back to the 1940’s of the last century. The therapeutic use of Nitrogen Mustard for certain hematological malignancies was first reported by Goodman et al. (1984). With the increasing understanding of cancer biology and molecular genetics a variety of Oral Anti-Cancer Agents (OAAs) are developed targeting key cellular mechanisms involved in tumour resistance to conventional therapies. It is estimated that 25% of all targeted anticancer agents will be oral medications and more than 400 oral agents are in the development pipeline (Weingart et al., 2008). They are used as single agents or in combinations to treat a variety of different cancers. In the last decades a tremendous expansion in the indications of OAAs has taken place in solid tumours and hematological malignancies (Timmers et al., 2012). They belong to different classes of medications with different modes of action and different toxicity profiles. The OAAs have many potential advantage including reducing costs by decreasing the utilization of valuable resources such as beds, infusion areas and health care providers time. It is also preferred by many patients as it reduces the need and risks of invasive devices such as central venous catheters, save time, ease of administration and more gives them a feel of control of their mediations (Schott et al., 2011, Liu et al., 1997, O’Neill and Twelves, 2002). There are however several challenges associated with the increasing use of OAAs pertinent to patients, caregivers, health care providers and hospital safety systems. Patients concerns include adherence, understanding complex schedules, different side effect profiles, interactions with foods and other medications and increase reliance on them to manage these medications. The health care providers particularly pharmacists are facing the challenges of updating their knowledge, reducing medications errors, safe handling, educations of patient and their caregivers and managing side effects. The safe handling policies and procedures for OAAs are not well developed as the parenteral anticancer agents. The practice of dispensing anti-cancer agents is variable. In many countries such as the United States and Canada, these agents are dispensed and managed primarily by a community Pharmacists. It is therefore not surprising that the published studies addressed these challenges in all aspects of OAAs imposed on community Pharmacists. In other countries the OAAs are dispensed only in cancer centres or specialized hospitals with cancer care facility and not dispensed in community Pharmacy. We intended to address these issues facing specialized Oncology Pharmacists dealing routinely with OAAs in the latter setting of specialized centres with cancer care facility.

Material and methods

Pharmacists involved in dispensing and handling OAAs at three tertiary care centres with oncology services namely King Fahad Medical city, King Saud Medical City and King Faisal Specialist Hospital and Research Center in Riyadh, Saudi Arabia, were included. All participants gave verbal consent and participation was voluntary. The study was cross sectional and extended from March 2013 to May 2014. King Faisal Hospital had a dedicated Oncology Pharmacy and the first two centres had dedicated pharmacists in the main outpatient pharmacy dispensing and managing the OAAs. We designed a structured questionnaire consisting of 41 questions testing 3 domains namely safe handling of OAAs including Patients caregivers’ education, Knowledge of OAAs medication (usage, indications, side effects, and drug interactions) and Pharmacists Attitudes (Confidence towards dispensing OAAs and self-improvement strategies). Multiple choice questions were used for testing the domains of OAAs knowledge. While the answers for the safe handling domain included true, false and choose what were applicable. All correct/incorrect and don’t know answers are expressed in percentages. The face value of the questionnaire was validated by 4 pharmacists and revised by a medical oncologist. The main revision was to include only OAAs that are standard treatment and available for several years and in all three centres. The knowledge questions excluded newly approved medications (within the last 1 year) even if available at one of the centres. One hundred and twenty Pharmacists answered the questionnaire. Statistical Considerations: Descriptive statistics was used applying SSPS version 21.

Results

The characteristics of the participants are shown in Table 1.
Table 1

Participants’ characteristics.

NationalitySaudi82%N = 98
Non-Saudi18%N = 22
GenderFemale64%N = 77
Male36%N = 43
Job descriptionPharmacy manager2.6%N = 3
Clinical pharmacist12%N = 14
Oncology pharmacist85.4%N = 103
Years of experienceLess than 3 years37%N = 44
3–6 years38%N = 46
7–10 years11%N = 13
More than 10 years14%N = 17
DegreePost-graduate degree12%N = 14
Bachelor Degree88%N = 106
Domain 1 studied the dispensing and safe handling of OCDs with 8 questions. Although 75% acknowledge the application of general principles of dispensing and safe handling of OAAs, the overall correct answers, incorrect answers and don’t know were 48%, 32% and 20% respectively. The use of a separate counting tray was acknowledged by 93% of pharmacist. Only one third thought protective gloves were needed during dispensing OAAs and 43% did not believe double checking was needed. Only 20% of pharmacist acknowledged they provided patients and their caregivers directions about safe handling of OAAs. The results are shown in Table 2.
Table 2

Safe handling and dispensing of anti-cancer agents.

Domain 1 Safe handling and dispensing of anti-cancer agentsNo of questionsCorrect (%)Incorrect (%)I don’t know (%)
Dispensing and safe handling of OCDs8483220
Know and apply the safety principles of dispensing and safe handling175187
Recommendation for safe handling1373330
Directions to patients and care givers about safe handling1203940
Strategies to improve safe handling1353431
Safe dispensing (if the patient unable to swallow)1303733
Separate counting tray for oral chemotherapy drugs1YesNo
937
Required double checking1YesNo
5743
Wearing Glove during dispensing1YesNo
3466
The second domain was testing the knowledge of pharmacists about OCDs. This included 31 questions that covered 4 areas. These four areas and the results are shown in Table 3.
Table 3

Knowledge of pharmacists about oral anticancer agents.

Domain 2NumberCorrect (%)Incorrect (%)I don’t know (%)
Drug knowledge30
A-General knowledge11233542
B-Side effects7143650
C-Dosing knowledge4185032
D-Drug drug interaction8224533
The overall knowledge of pharmacists about OAAs was poor. Pharmacists were least knowledgeable about dosing and side effects. Only 14% answered the questions related to side effects correctly and half of pharmacist were not sure about the side effects associated with each medication. The third domain was the attitudes of the pharmacist towards OAAs, the gaps in formal education and strategies of self-improvement. Only 26% felt somewhat confident to dispense OAAs. A quarter acknowledged they received education about OAAs in college or later in their practice. The majority agreed they would participate in further educations about OAAs and online learning was the preferred method to enhance knowledge. These results are shown in Table 4.
Table 4

Attitude and self improvement.

Domain 3 attitude and self improvementNo of questions
Pharmacist attitude4
Confident about dispensing oral chemotherapy1ConfidentSomewhat confidentNeutralNot confidentI don’t know
18%8%16%14%44%



Education about oral anti-cancer agents (Collage or postgraduate)1YesNoI’m not sure
28%55%17%
Attend a course or continuing education1YesNoI don’t know
70%23%7%
Preferred format of continuing education1Lectures written materialsOnline courses video seminarsNo response
7%63%30%

Discussion

OAAs are different from many medications as they pose risks to health care providers, patients and their caregivers even with what is considered a standard use. Special precautions are required for safe dispensing and handling of these medications. Pharmacists are at the frontline in providing care when it comes to oral medications and contribute to overall safety and outcomes of these therapies. Our study highlights that there are serious gaps in Pharmacists Knowledge about OAAs and there is a general lack of confidence and ability to educate patients and their caregivers. Previous published studies have focused on community pharmacists as handling and dispensing these medications take place primarily in the community setting. In a study across Canada only 24% knew about the common dosing and less than 10% felt confidence in educating patients and caregivers about OAAs (Abbott et al., 2014). In a US study community Pharmacists fared better knowledge about dosing principles but knowledge about side effects remained suboptimal (45%) (O’Bryant and Crandell, 2008). Pharmacists expressed they did not receive adequate education at the undergraduate level 55% in our study and 59% in the Canadian study (Abbott et al., 2014). Our study showed a low confidence towards dispensing OAAs, similarly in the US study the confidence towards dispensing was scored as 2.4/5 on a five point scoring system (O’Bryant and Crandell, 2008). These studies including ours highlight important fact that knowledge gaps and suboptimal confidence are a concern among community and specialized pharmacists. The pharmacists uniformly agree that they need further education to boost their knowledge and confidence towards OAAs and to improve their ability to educate their patient and caregivers. When it comes to safe handling practices our study highlights important differences between community and hospital based practice. Safety guidelines exists in hospital practice for OAAs evidenced by three quarters of Pharmacists acknowledging awareness of safety principles, higher rate of separate counting trays, use of protective clothing and double checking. Almost 95% of US community pharmacist were not using a separate counting tray compared to 93% using a separate tray in the specialized setting (O’Bryant and Crandell, 2008). Higher percentage have attended educational courses 70% in our study compared to 16% in the US pharmacist study (O’Bryant and Crandell, 2008). Despite safe handling principles and guidelines exists at facilities caring for cancer patients our study indicates their implementations remains suboptimal. It highlights that the interventions need to be tailored according to gaps in knowledge and deficiencies in safe handling and dispensing practice. Dispensing errors constitute about 15% of the Medication related errors. Studies have shown higher prescription of errors are related to OAAs (Weingart et al., 2010). Studies have shown pharmacists not applying safety standards are at risk of greater exposure to these cytotoxic medications. Urine samples taken from personal handling these medications have shown measurable amounts of these medications in 40% to two thirds of the personal who included pharmacists and other personal handling these medications (Pethran et al., 2003, Schreiber et al., 2003). Interventions by well-trained pharmacists have shown to improve the outcomes of many medical conditions (Machado et al., 2008, Chisholm-Burns et al., 2010). Therefore improving knowledge and safe handling practices are imperative and will undoubtedly improve patient outcomes and safety of the providers. There was a lack of uniform guidelines on safe handling and dispensing OAAs in the last decade. Expanding use of OAAs posing major concerns on safety of staff as well as patients and caregivers had led many groups to develop comprehensive guidelines and standards to enhance all aspects of the safety of OAAs (Goodin et al., 2011). One of the most comprehensive updated guidelines is the American Society of Clinical Oncology and Oncology Nursing society (ASCO/ONS) guidelines for safe administration and management of oral chemotherapy (Neuss et al., 2013). These guidelines intended to involve all the stakeholders, to be comprehensive and applicable to individuals and institutions. In a recent multinational study by the International Medication safety Practice (ISMP) and International Medication safety Practice Canada (ISMPC) addressing system based safeguards in Oncology practice identified OAAs as a key areas that needs improvement (Greenall et al., 2015). How to implement and adapt these guidelines and monitor their applications remains a major challenge. It is imperative to conduct research and quality improvement programs in different practice settings involving OAAs. These studies and quality projects will help in identifying areas of deficiency in knowledge and safe handling and will aid in the development of best assessment tools and interventions applicable to the relevant practice. A proposed schema for the potential improvement of the overall safety of the OAAs from a pharmacists perspective is shown in Fig. 1. Our studies’ results do have limitations which include the lack of a validated assessment tool, the inability to cover all aspects to safety and cross comparisons to a different practice in our analysis. Despite these limitations we still believe limited studies have addressed these issues and seem to reach a similar conclusion. We provide a prospective of practice different from the community pharmacy practice and highlight the complexity of this subject.
Figure 1

Towards better safety of oral anticancer agents.

Conclusions

The global burden of cancer is increasing. The expanding use of OAAs is posing major concerns on safety of personal, patients and their caregivers. The standards and guidelines for safe handling and dispensing of these agents a not abreast with the rapid and wide applications of these medications in clinical practice. After collaborative initiatives more comprehensive guidelines addressing safe handling and dispensing of OAAs have been developed, however their uniform implementations remains a major challenge. More studies are needed to identify the areas for improvement relevant to each practice. Pharmacists will remain a key player in safe handling and dispensing these medications as well as educating patients and caregivers. The published studies highlights major gaps in OAAs and safe dispensing. Medical schools, policy makers, institutions, researchers and patient advocates need to work together to improve pharmacists’ knowledge and competency as well as the safety of pharmacists, patients and caregivers handling the OAAs.
  17 in total

1.  Uptake of antineoplastic agents in pharmacy and hospital personnel. Part I: monitoring of urinary concentrations.

Authors:  Angelika Pethran; Rudolf Schierl; Karlheinz Hauff; Carl-Heinz Grimm; Karl-Siegfried Boos; Dennis Nowak
Journal:  Int Arch Occup Environ Health       Date:  2002-10-09       Impact factor: 3.015

2.  Use and costs of oral anticancer agents in the Netherlands in the period 2000-2008.

Authors:  Lonneke Timmers; Jan Jacob Beckeringh; Myrthe P P van Herk-Sukel; Epie Boven; Jacqueline G Hugtenburg
Journal:  Pharmacoepidemiol Drug Saf       Date:  2011-09-29       Impact factor: 2.890

Review 3.  US pharmacists' effect as team members on patient care: systematic review and meta-analyses.

Authors:  Marie A Chisholm-Burns; Jeannie Kim Lee; Christina A Spivey; Marion Slack; Richard N Herrier; Elizabeth Hall-Lipsy; Joshua Graff Zivin; Ivo Abraham; John Palmer; Jennifer R Martin; Sandra S Kramer; Timothy Wunz
Journal:  Med Care       Date:  2010-10       Impact factor: 2.983

Review 4.  NCCN Task Force Report: Oral chemotherapy.

Authors:  Saul N Weingart; Elizabeth Brown; Peter B Bach; Kirby Eng; Shirley A Johnson; Timothy M Kuzel; Terry S Langbaum; R Donald Leedy; Raymond J Muller; Lee N Newcomer; Susan O'Brien; Denise Reinke; Mark Rubino; Leonard Saltz; Ronald S Walters
Journal:  J Natl Compr Canc Netw       Date:  2008-03       Impact factor: 11.908

5.  Medication errors involving oral chemotherapy.

Authors:  Saul N Weingart; Julio Toro; Justin Spencer; Deborah Duncombe; Anne Gross; Sylvia Bartel; Jeremy Miransky; Ann Partridge; Lawrence N Shulman; Maureen Connor
Journal:  Cancer       Date:  2010-05-15       Impact factor: 6.860

6.  Patient preferences for oral versus intravenous palliative chemotherapy.

Authors:  G Liu; E Franssen; M I Fitch; E Warner
Journal:  J Clin Oncol       Date:  1997-01       Impact factor: 44.544

7.  Global cancer transitions according to the Human Development Index (2008-2030): a population-based study.

Authors:  Freddie Bray; Ahmedin Jemal; Nathan Grey; Jacques Ferlay; David Forman
Journal:  Lancet Oncol       Date:  2012-06-01       Impact factor: 41.316

8.  Uptake of antineoplastic agents in pharmacy personnel. Part II: study of work-related risk factors.

Authors:  Claudia Schreiber; Katja Radon; Angelika Pethran; Rudolf Schierl; Karlheinz Hauff; Carl-Heinz Grimm; Karl-Siegfried Boos; Dennis Nowak
Journal:  Int Arch Occup Environ Health       Date:  2002-10-09       Impact factor: 3.015

9.  Acceptance of oral chemotherapy in breast cancer patients - a survey study.

Authors:  Sarah Schott; Andreas Schneeweiss; Judith Reinhardt; Thomas Bruckner; Christoph Domschke; Christof Sohn; Michael H Eichbaum
Journal:  BMC Cancer       Date:  2011-04-12       Impact factor: 4.430

Review 10.  Oral cancer treatment: developments in chemotherapy and beyond.

Authors:  V J O'Neill; C J Twelves
Journal:  Br J Cancer       Date:  2002-10-21       Impact factor: 7.640

View more
  1 in total

1.  Prospective evaluation of an anti-cancer drugs management programme in a dedicated oral therapy center (DICTO programme).

Authors:  Elise Deluche; Tiffany Darbas; Kevin Bourcier; Loic Montangon; Geraldine Bayard; Evelyne Caille; Julie Querrioux; Chantal Suchaud; Sonia Zabaleta; Sabine Chaput; Valerie Le Brun-Ly; Julia Pestre; Laurence Venat; Frédéric Thuillier; Elodie Nevado; Gaelle Maillan; Jeremy Jost; Sophie Leobon; Nicole Tubiana-Mathieu; Sandrine Lavau-Denes
Journal:  Med Oncol       Date:  2020-07-25       Impact factor: 3.064

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.